cyrilzakka/clinical-trials huggingface dataset:
Oral Cancer Awareness in Egypt

Oral cancer is a fatal disease with high prevalence and poor survival rate. Most oral cancer cases can be detected by the patients themselves. So, when a patient is aware of oral caner, the patient would realize its signs and symptom and seek early medical care; therefore, improving the prognosis.

To our knowledge, the level of awareness of oral cancer has not been investigated in Egyptian population. Therefore, this study is planned to be a pilot study as a first study in Egypt.

Cancer of the oral cavity is considered a global health burden. According to GLOBOCAN report of 2012, the incidence of oral cancer in Egypt was 1,687 per 10,000 per annum; while the mortality was 659 per 10,000 per annum. Statistically, the rates are expected to increase as to reach 2,658 per 10,000 incidence and 1,069 per 10,000 mortality by the year 2030.

Fortunately, 85% of head and neck cancers are visible. Therefore, the patient does not always need to visit a specialist for a special test to check for oral cancer. Instead, if the patients have basic knowledge about oral cancer, its signs and symptoms and its risk factors, they can detect the change themselves.

As a first step to reach this amazing goal, the level of awareness of the general population needs to be detected.

To the best of our knowledge, the awareness of oral cancer has not been assessed in the general population of Egypt before. As awareness of oral cancer is mandatory for dental practitioners, our study targets the general population other than those working in the dentistry field.

Eligibility Criteria:
Inclusion criteria:

* Adult individuals (Age\>18 years).

Exclusion criteria:

* Dental students or dental practitioners; as awareness of the disease is an integral part of their profession.
* Oral cancer patients: Individuals who experience currently or previously having oral cancer.
* Individuals with mental or communication disabilities.
Sleep Problems in Epileptic Children and Their Caregivers

The aim of this study is to investigate the frequency of sleep problems in epileptic children and their caregivers.

The study instruments include two parts. First, data on socio-demographic, height, weight, the sleep duration, caregiver's level of education (Illiterate, Preliminary school, High school, University), caregiver sleep problems, and medical background were noted. Clinical data regarding epilepsy (a type of seizure, etiology, the frequency of seizures, actual and previous antiseizure medications) were collected from interviews of participants/parents and examination. Second, the psychometric assessment tools used to evaluate all participants and caregivers; Children's sleep habits questionnaire (CSHQ), strength and difficulties questionnaire (SDQ), diagnostic and statistical manual of mental disorders (DSM)-V Sleep Disorders Scale-Child Report, DSM-V Sleep Disorder Scale- Adult Report. All participants and their caregivers completed the psychometric questionnaires.

Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of epilepsy that based on the International League Against Epilepsy (ILAE) operational clinical definition criteria for epilepsy
* must be diagnosed by pediatric neurologists
* must receive treatment for at least one year.

Exclusion Criteria:

* to have an IQ ≤80, as measured by the Wechsler Intelligence Scale for Children-Revised Form (WISC-R) or below-average academic performance documented by last year's final school grade
* to have a history of psychiatric, developmental disorder, or psychosis
* to have a history of progressive neurological disorder other than epilepsy
* to have any complaint (e.g., behavior problems, depression, or anxiety) that could interfere with sleep
* to have a caregiver who has any medical or psychiatric condition (e.g., depression or anxiety) that could interfere with sleep.
The Effects of a Novel Nutritional Product on Nutrient Gaps and Gut Health in Active Adults

This study is a randomized, double-blind, placebo-controlled study of N=20 active men and women. This study to assess the effect of a novel dietary supplement on improving nutrient gaps and the gut microbiome.


Eligibility Criteria:
Inclusion Criteria:

* Provide voluntary signed and dated informed consent.
* Be in good health as determined by medical history and routine blood chemistries.
* \> 1 year of resistance training experience (minimum of 2 days per week of resistance training session with free weights)
* Age between 18 and 40 yr (inclusive).
* Subject agrees to maintain existing dietary and physical activity patterns throughout the study period.
* Subject is willing and able to comply with the study protocol.

Exclusion Criteria:

* History of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal conditions.
* History of diabetes or endocrine disorder.
* History of use of medications or dietary supplements known to confound the study or its endpoints.
* Alcohol consumption (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) or drug abuse or dependence within the past 6 months.
* Current smokers or smoking within the past month.
* History of hyperparathyroidism or an untreated thyroid condition.
* History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
* Prior gastrointestinal bypass surgery (Lapband), etc.
* Other known gastrointestinal or metabolic conditions that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, Irritable bowel syndrome (IBS), diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU).
* Chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's, ulcerative colitis, Lupus, HIV/AIDS, etc.).
* Previous medical diagnosis of asthma, gout, or fibromyalgia.
* Pregnant women, women trying to become pregnant, women less than 120 days postpartum or nursing women.
* Known sensitivity to any ingredient in the test formulations as listed in the product label.
* Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
* Any other conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.
Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH

The purpose of this study is to examine N-terminal pro brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP) biomarkers in a number of different settings including assessing the repeatability of laboratory and point of care testing (POCT), the effect of a time delay and exercise have on laboratory measurements. Also to compare the clinical and analytical performances of NT-proBNP and BNP POCT samples across the spectrum of disease severity and finally assess whether POCT in PAH can detect change in patients commencing or escalating PAH treatment.

* Patients that are attending clinical appointments will be approached to ask if they will take part in the study.
* Patients will be assessed at two separate visits.
* Patients will be randomised to either exercise or rest group on their 1st visit. On the 2nd visit patients will be asked to participate in the alternate group to what they completed on their previous visit.
* At each visit they will have 2 blood samples taken, at time point 1 and at time point 2 (T1 and T2). These will be taken at least one hour apart, each with a period of at least 15 mins rest in the sitting position prior to sampling.
* On one of these two visits the patient will undergo exercise testing between T1 and T2.
* In addition, a further laboratory testing tube will be taken for a delayed NT-proBNP. This will be subjected to gentle agitation (laboratory rotator) for 48 hours prior to processing to simulate, in a controlled environment, the effect of transport and delay on sample measurement.
* Retrospectively information will be collected regarding the patient's disease severity and any change to treatment that occurred between the two visits.
* A total of 40 patients with be sampled with an interim analysis after 20 patients.

Eligibility Criteria:
Inclusion Criteria:

* Patients who have met the criteria for The Sheffield Teaching Hospitals Observational Study of Patients with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-ObS)
* Patient diagnosed with Group 1 PAH, including IPAH, HPAH, PAH-CTD but excluding PAH-CHD. Mean pulmonary artery pressure \>20mmHg, PAWP ≤15mmHg and PVR \>240 dynes.
* Willing to participate in the study and able to provide informed consent

Exclusion Criteria:

* Diagnosed with PAH-CHD or any non-group 1 PH
* Creatinine clearance \< 15 ml/min/m2
Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard Colonoscopy

The purpose of this study is to compare the adenoma detection rate (ADR) of the G-EYE™ colonoscopy with that of standard colonoscopy.

This is a single-center, two-arm , randomized, open-label study intended to compare the detection rate obtained by performing G-EYE™ colonoscopy vs. the detection rate obtained by performing standard colonoscopy.

The study will enroll 350 subjects. Consecutive adult subjects who were referred for elective colonoscopy will be asked to enroll in this randomized clinical study if the candidate meets the study inclusion and exclusion criteria.

Subjects will sign an informed consent form and undergo randomization.

Eligibility Criteria:
Inclusion Criteria:

1. Patients over 50 years old
2. Referred to colonoscopy for screening, following positive FOBT testing, change of bowel habits, for diagnostic evaluation or for surveillance colonoscopy (history of adenoma resection).
3. The patient must understand and provide written consent for the procedure.

Exclusion Criteria:

1. Subjects with inflammatory bowel disease;
2. Subjects with a personal history of polyposis syndrome;
3. Subjects with suspected chronic stricture potentially precluding complete colonoscopy;
4. Subjects with diverticulitis or toxic megacolon;
5. Subjects with a history of radiation therapy to abdomen or pelvis;
6. Pregnant or lactating female subjects;
7. Subjects who are currently enrolled in another clinical investigation.
8. Subjects with current oral or parenteral use of anticoagulants that have not stopped using anticoagulants as required by the guidelines of the medical center;
9. Subjects with recent (within the last 3 mounts) coronary ischemia or CVA (stroke)
10. Any patient condition deemed too risky for the study by the investigator
11. Previous colonic surgery (except for appendectomy)
The Effect of Supplementing Different Solutions on Firefighters' Simulated Fire Rescue Training

One of the three major tasks of firefighters is disaster rescue, and fire rescue accounts for the majority. They must wear personal protective equipment (PPE) at the fire site during execution. This set of equipment plus other equipment required for rescue will always It weighs up to 40 kg, and the rescue environment is extremely hot and the rescue mission must be carried out in a short time. Under this extremely high pressure, firefighters must have speed, agility, strength and endurance that are different from ordinary people. However, after performing the above fire rescue tasks, firefighters often lose a lot of water; therefore, the purpose of this study is to explore the impact of water and electrolyte supplementation on physical recovery after firefighters perform fire rescue tasks. A total of 24 field firefighters from the Fire Department were research subjects.

In the past research on firefighters, there was no research on the effect of water and electrolyte supplementation on physical recovery after dehydration after performing fire rescue tasks. Therefore, in this study, the body composition was measured before and after the special training of firefighters simulated fire rescue. , Collect venous blood; Replenish electrolytes in sections after training, and take venous blood, urine and saliva for tests at 15, 30 and 60 minutes to analyze relevant values and perform strength tests to observe firefighters The state of physical recovery.

The experiment was divided into three groups. The control group only drank 1 liter of pure water, the sports drink group was supplemented with commercially available sports drinks, and the mint flavored sports drink group was supplemented with mint flavored commercially available sports drinks. Drink 1 liter of liquid within 60 minutes after training; 8 people in each of the 3 groups are randomly assigned. The results of the experiment were analyzed by analysis of variance (ANOVA), and Tukey-Kramer test was used to detect whether there are differences between different treatments, and P\<0.05 represents statistical significance.


Eligibility Criteria:
Inclusion Criteria:

- male firefighters aged between 20 and 50

Exclusion Criteria:

* cardiovascular disease hypertension metabolic syndrome glucose-6-acid dehydrogenase deficiency
Additional Effects of Transversus Abdominial Strengthening Along With Pelvic Floor Muscle Strengthening on Stress Urinary Incontinence Among Multiparous Women

SUI stands for stress urinary incontinence. A common condition seen among multiparous women associated with physical strain like bending, coughing, sneezing that put strain on the pelvic floor muscles.


Eligibility Criteria:
Inclusion Criteria:

* Age group: multiparous women ( 30-50 yrs)
* females only
* all modes of delivery of childbirth
* diagnosed cases of SUI from fauji foundation hospital.
* patient without any medical contraindications and limitations (Sign and Symptoms of SUI)
* accordances with the michigan incontinence index

Exclusion Criteria:

* pregnancy or recent childbirth
* any history of pelvic organ prolapse or surgical intervention
* metabolic diseases, uncontrolled hypertension as well as neurological intervention
* any kind of malignancy in lower abdomen
A Combined Lifestyle Intervention Delivered by Physio/exercise Therapists for Patients with Persistent Low Back Pain and Overweight or Obesity

Low back pain (LBP) is the leading cause of disability worldwide and is costly. Lifestyle factors, such as physical inactivity, stress, sleep, excess weight, and an unhealthy diet contribute to the burden of LBP and the associated increasing demand for care. Moreover, approximately 65% of LBP patients who visit the hospital are overweight. This group is considered a complex patient group. Of the LBP patients who visit the hospital, 74% are referred back to primary care as medical specialists cannot offer them high value care. Targeting both lifestyle factors (e.g., physical activity, sleep and stress) and clinical factors related to low back pain (e.g., muscle strength, endurance, mobility) is important in the management of this group of LBP patients to improve important outcomes (e.g., functioning, physical activity) and reduce costs. Addressing lifestyle factors may also offer additional health benefits like decreased risks of diabetes and cardiovascular diseases.

The primary objective of this project is to improve the management of this complex group of LBP patients, that is, patients who are overweight or obese and who are referred back to primary care from the hospital because medical specialists cannot offer them high value care, and to reduce healthcare and societal costs. The primary research question is: 'Is a combined lifestyle intervention, integrated into standard care for LBP, delivered by physio/exercise therapists effective and cost-effective in improving physical functioning and/or physical activity over a 36-month period compared to usual care in overweight or obese LBP patients who are referred back from the hospital to primary care?' It is hypothesized that the combined lifestyle intervention, integrated into standard care for LBP, is both effective and cost-effective in managing LBP in patients who are overweight or obese over a 36-month period.


Eligibility Criteria:
Inclusion Criteria:

* Patients with persistent (≥3 months) non-specific LBP who are referred back from the hospital to primary care
* Either BMI≥30 OR BMI≥25 with at least one comorbidity (osteoarthritis, sleep apnea, risk factors for cardiovascular diseases or type 2 diabetes)
* Decreased physical functioning (RMDQ ≥4 out of 24)
* Average LBP intensity of ≥3 out of 10 over the past week (NPRS)
* ≥18 years old

Exclusion Criteria:

* Specific LBP (e.g., tumor or fracture)
* Back surgery in the past six months
* Psychiatric diseases that could hinder participation
* Pregnancy or ≤9 months postpartum
Study for the Treatment of Crohn's Disease With Adacolumn

The purpose of this study is to evaluate the safety and effectiveness of the Adacolumn Apheresis System as a treatment for the signs and symptoms of Crohn's disease.

Trial Features:

* Medical device (Non-drug option)
* Most patients can remain on current treatment regimen throughout the study

Components of the Study:

* Study length is 24 weeks, which includes a screening visit, ten treatment visits over nine weeks and 4 follow-up appointments
* Physical exams, laboratory tests and disease assessments conducted at no charge to the patient
* 2:1 Randomization (treatment:sham)
* Open-Label extension offered to eligible patients

Eligibility Criteria:
Key Inclusion Criteria:

* Moderate to severe Crohn's disease
* Adequate peripheral venous access
* Agree to participate in the required follow-up visits
* Able to complete a diary
* Signed written informed consent document and authorization for use of protected health information

Key Exclusion Criteria:

* Extremely severe Crohn's disease
* Known obstructive symptoms within the past 3 months
* Presence of toxic megacolon
* Major surgery within the past 6 weeks or anticipated need for surgery within 12 weeks
* Total colectomy, ileostomy, stoma or 100 cm of resected small bowel
* Requiring in-patient hospitalization
* A history of allergic reaction to heparin or heparin-induced thrombocytopenia
* A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures
* A history of severe cardiovascular or peripheral arterial diseases
* A history of cerebral vascular diseases
* Liver diseases
* Renal insufficiency
* Known bleeding disorder or use of concomitant anticoagulant therapy for purposes other than apheresis treatment
* Any hypercoagulable disorder
* Known infection with Hepatitis B or C, or HIV
* Severe anemia
* Leukopenia or granulocytopenia
* Evidence of current systemic infection
* Malignancy
* Pregnant, lactating or planning to become pregnant during the course of the investigational study
* Used within the last 30 days, an investigational drug, biologic or device or 5 half-lives, if known, for any investigational drug or biologic
Laboratory Testing for Tie-2 Expressing Monocytes (TEMs) in Blood

Tie-2 expressing monocytes (TEMs) are a specific type of blood cell that are present in healthy individuals and in people with cancer. These cells may play a role in the growth of blood vessels (veins/arteries), and may be particularly important in the growth of blood vessels that supply tumours. Understanding how these cells work may therefore help researchers to develop cancer treatments that starve tumors of their blood supply.

This research study involves an analysis of the behaviour of blood cells in response to different drugs in a test tube. The goal is to develop tests that can then be used to monitor patients treated with drugs that target blood vessel growth.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers

  * Ability to understand and the willingness to sign a written informed consent document.
* Patients with advancer cancer

  * Participants must have histologically confirmed metastatic or unresectable solid tumors.
  * Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Healthy volunteers

  * History of cancer within the past 5 years
  * Major medical condition undergoing active therapy
* Patients with advancer cancer

  * Active hematologic malignancy (leukemia, lymphoma, myeloproliferative disorder).
  * Active treatment on a Phase I clinical trial
Prenatal Breastfeeding Education to Reduce Nipple Pain

This study is a randomized controlled trial to evaluate the effectiveness of different approaches to prenatal teaching of infant latch.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant women who intend to breastfeed their infants
* Single infant
* Resides in catchment area
* Has phone
* Speaks English
Feasibility of Early Gabapentin as an Intervention for Neurorecovery

The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.

Gabapentin is a medication commonly used in spinal cord injury (SCI) to manage neuropathic pain. Emerging preclinical and clinical evidence suggests that early initiation of low to medium doses of gabapentin and continued delivery for a range of 2 weeks to 4 months has a persistent, positive effect on motor and autonomic neurologic recovery. The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the early administration of gabapentin as an intervention for neurorecovery. A mock efficacy design will be employed. Participants will be stratified based on ASIA Impairment Scale (AIS) grade A-B or C-D and randomized to 1 of 3 arms. Study medication will be initiated within 5 days post-injury and administered for 90 days. Participants will be followed for an additional 90 days after stopping treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Traumatic SCI;
2. All levels of SCI;
3. All severities of SCI, AIS A-D;
4. Age 18 years and older.
5. Agree to participate and start study drug within 120 hours' post-injury.
6. Adequate cognition and communication to provide informed consent

Exclusion Criteria:

1. Presence of moderate/severe traumatic brain injury (TBI) as defined by Glasgow Coma Score (GCS) \< 13 at 120 hours' post-injury.
2. Documented use of gabapentinoids at the time of injury.
Clinical Evaluation of Two Daily Disposable Lenses in a Population of Daily Disposable (DD) Lens Wearers

The purpose of this study is to evaluate the performance of two daily disposable contact lenses in a population of daily disposable contact lens wearers.


Eligibility Criteria:
Inclusion Criteria:

* Currently wearing any spherical daily disposable contact lens except the two study products for at least 3 months prior to enrollment.
* Currently wearing contact lenses at least 8 hours/day and 5 days/week.
* Other protocol inclusion/exclusion criteria may apply.

Exclusion Criteria:

* Eye injury or surgery within twelve weeks immediately prior to enrollment.
* Currently enrolled in any clinical trial.
* Prior history of corneal or refractive surgery.
* Monovision correction.
* Other protocol inclusion/exclusion criteria may apply.